https://www.selleckchem.com/pr....oducts/golvatinib-e7
74-0.87) and females (HR 0.83, 95% CI 0.76-0.9 had better OS when treated with chemoimmunotherapy than chemotherapy alone, with no statistically significant interaction between sex and receipt of immunotherapy (p = 0.63). Propensity matching confirmed these results. However, for those with squamous cell histology, male patients derived more benefit from chemoimmunotherapy treatment than females (HR 0.73, 95% CI 0.58-0.91 vs HR 1.03, 95% CI 0.76-1.38; p for interaction = 0.07). Male patients with squamous cell carcinoma may de
Like
Comment
Share
